A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 10
- Population
- ALL · 18 Years
- Duration
- 2020-12-09 to 2023-02-14
- Intervention
- Dextenza 0.4Mg Ophthalmic Insert; Prednisolone Acetate
- Comparator
- Topical Corticosteroids
- Outcomes measured
- Mean Change in Pain Scores — As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 d…; Overall Proportion of Eyes with Absence of AC Cell/Flare (Score of 0) — Assessed 3-6 days following Injection Visit 1,…; Proportion of eyes with absence of AC cells/flare (score of 0) — Assessed at 3-6 days following Injection Visit 1, Inje…; Correlation of pain scale outcomes with absence or presence of AC cell count and flare scores — Assessed at 3-6 days af…; Mean Change in pain scores — As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 d…; Patient Comfort — As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 days after I…; Mean Change in Tear Break-up Time — As assessed at Baseline Visit, Injection Visit 1, Injection Visit 2, Injection Visi…; Mean Change in Snellen and Pinhole Acuity — As assessed at Baseline Visit, Injection Visit 1, Injection Visit 2, and In…; Mean change in IOP — As assessed at Baseline Visit, Injection Visit 1, Injection Visit 2, and Injection Visit 3, and th…; Patient Preference — As assessed at the Final Post-Injection Follow-up Visit (up to 24 weeks); Incidence and severity of adverse events — As assessed at Baseline, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), 3-6…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.